Download pdf
Underlying factors that may affect the treatment of Platelet-rich plasma in chronic wounds
- 1 The First Affiliated Hospital of Jinan University
- 2 Jinan University
* Author to whom correspondence should be addressed.
Abstract
Platelet-rich plasma (PRP) has gained widespread usage in the treatment of various chronic wounds due to its ease of preparation and high safety profile. But not every treatment can achieve satisfactory results. The quality of PRP is based on individual biological characteristics. Autologous PRP technology is greatly affected by the patient himself. Individual responses to PRP treatment are different and will produce different therapeutic effects. Especially in patients with uncontrollable factors such as aging, diabetes, and coronary heart disease, the use of antiplatelet drugs may potentially reduce the quality of autologous platelet-rich plasma (PRP). When treating related diseases, it is important to consider the impact of factors such as age, gender, and the specific disease. Currently, many researchers are focusing on the development of allogeneic PRP technology to avoid the inconvenience of collecting autologous blood and reduce potential negative effects that may exist in the patient's disease itself. In this review, we explore the factors generally recognized in current research which influence the efficacy of PRP.
Keywords
platelet-rich plasma, chronic wounds, autologous, allogeneic
[1]. Gold, M.H., J.A. Biron, and W. Sensing, Facial skin rejuvenation by combination treatment of IPL followed by continuous and fractional radiofrequency. J Cosmet Laser Ther, 2016. 18(1): p. 2-6.
[2]. Mussano, F., et al., Cytokine, chemokine, and growth factor profile of platelet-rich plasma. Platelets, 2016. 27(5): p. 467-71.
[3]. Senzel, L., D.V. Gnatenko, and W.F. Bahou, The platelet proteome. Curr Opin Hematol, 2009. 16(5): p. 329-33.
[4]. Li, T., et al., Platelet-rich plasma plays an antibacterial, anti-inflammatory and cell proliferation-promoting role in an in vitro model for diabetic infected wounds. Infect Drug Resist, 2019. 12: p. 297-309.<富血小板血浆对痤疮丙酸杆菌的体外抑菌实验研究_吕品.pdf>.
[5]. Zhang, W., et al., Platelet-Rich Plasma for the Treatment of Tissue Infection: Preparation and Clinical Evaluation. Tissue Eng Part B Rev, 2019. 25(3): p. 225-236.
[6]. Anitua, E., et al., Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost, 2004. 91(1): p. 4-15.
[7]. Senzel, L., D.V. Gnatenko, and W.F. Bahou, The platelet proteome. Curr Opin Hematol, 2009. 16(5): p. 329-33.
[8]. Jeong, S.H., S.K. Han, and W.K. Kim, Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg, 2010. 125(3): p. 944-52.
[9]. Perseghin, P., et al., Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds. Transfusion, 2005. 45(9): p. 1544-6.
[10]. Salini, V., et al., Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. Front Aging Neurosci, 2015. 7: p. 228.
[11]. Middeldorp, J., et al., Preclinical Assessment of Young Blood Plasma for Alzheimer Disease. JAMA Neurol, 2016. 18.3(11): p. 1325-1333.
[12]. Taniguchi, Y., et al., Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop, 2019. 6(1): p. 4.
[13]. Delgado, D., et al., Biological and structural effects after intraosseous infiltrations of age-dependent platelet-rich plasma: An in vivo study. J Orthop Res, 2020. 3.5(9): p. 1931-1941.
[14]. Delgado, D., et al., Effects of Platelet-Rich Plasma on Cellular Populations of the Central Nervous System: The Influence of Donor Age. Int J Mol Sci, 2021. 22(4).
[15]. Kahal, H., et al., Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes Metab, 2018. 44(5): p. 431-436.
[16]. Braun, H.J., A.S. Wasterlain, and J.L. Dragoo, The use of PRP in ligament and meniscal healing. Sports Med Arthrosc Rev, 2013. 21(4): p. 206-12.
Cite this article
Dong,Z.;Wu,J. (2023). Underlying factors that may affect the treatment of Platelet-rich plasma in chronic wounds. Advances in Engineering Innovation,5,1-5.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Journal：Advances in Engineering Innovation
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).